The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value - Report - MDSpire
Advertisement
The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value
Effectiveness of PHI Combined with mpMRI for Prostate Cancer Diagnosis by PSA Level
Overview
This study evaluated the diagnostic performance of the Prostate Health Index (PHI) combined with multiparametric MRI (mpMRI) in detecting prostate cancer (PCa) across different PSA levels. The combination improved detection accuracy, particularly for clinically significant prostate cancer (csPCa), and reduced unnecessary biopsies compared to PSA or mpMRI alone.
Background
Prostate cancer remains a leading cause of cancer-related death in men worldwide, with early and accurate diagnosis critical for improving outcomes. PSA testing, while widely used, has limitations including low specificity leading to overdiagnosis and unnecessary biopsies. The Prostate Health Index (PHI) and mpMRI have emerged as promising tools to enhance diagnostic precision. Combining PHI with mpMRI may better identify clinically significant disease and guide biopsy decisions, but their combined diagnostic value across varying PSA levels requires further investigation.
Data Highlights
Parameter
Value
Total patients analyzed
120
PCa cases detected
48 (40.0%)
Clinically significant PCa (csPCa)
37 (30.8%)
Patients with negative mpMRI (PI-RADS <3)
33
PCa detected in negative mpMRI group
3 (9.1%), including 2 csPCa
Patients with PI-RADS 3
48
PCa in PI-RADS 3 group
12 (25.0%), including 8 csPCa
Patients with PI-RADS >3
41
PCa in PI-RADS >3 group
23 (27.5%)
Key Findings
PHI combined with mpMRI demonstrated superior diagnostic accuracy for PCa compared to PSA or mpMRI alone.
Among patients with PSA levels between 4-10 ng/ml, the combination improved detection of clinically significant prostate cancer.
mpMRI alone had false negatives, as 9.1% of patients with negative mpMRI still had PCa detected on biopsy.
PI-RADS scoring correlated with PCa detection rates: higher scores associated with increased PCa and csPCa prevalence.
Combining PHI with mpMRI reduced unnecessary biopsies by better stratifying patients at risk.
The study supports the use of PHI and mpMRI together to improve clinical decision-making in prostate cancer diagnosis.
Clinical Implications
Incorporating PHI testing alongside mpMRI can enhance the detection of clinically significant prostate cancer, particularly in patients with PSA levels in the 4-10 ng/ml range. This combined approach may reduce unnecessary biopsies and associated complications by better identifying patients who truly require tissue diagnosis. Clinicians should consider integrating PHI with mpMRI findings to optimize prostate cancer diagnostic pathways.
Conclusion
The combination of PHI and mpMRI improves diagnostic accuracy for prostate cancer over either modality alone, especially for clinically significant disease. This strategy holds promise for refining biopsy decisions and improving patient management.
References
Gnanapragasam et al. 2019 -- Combining mpMRI and PHI reduces repeat biopsies
FDA 2012 -- Approval of PHI for PSA 2.0-10.0 ng/ml range
PRECISION Study 2018 -- Prebiopsy mpMRI excludes non-significant PCa
